These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17433023)

  • 1. Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin).
    Prager F; Michels S; Geitzenauer W; Schmidt-Erfurth U
    Acta Ophthalmol Scand; 2007 Dec; 85(8):904-6. PubMed ID: 17433023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
    Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
    Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juxtafoveal choroidal neovascularization secondary to persistent placoid maculopathy treated with intravitreal bevacizumab.
    Parodi MB; Iacono P; Bandello F
    Ocul Immunol Inflamm; 2010 Oct; 18(5):399-401. PubMed ID: 20666681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
    Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
    Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV; Steén B; Seregard S; Kvanta A
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.
    Arias L; Planas N; Prades S; Caminal JM; Rubio M; Pujol O; Roca G
    Br J Ophthalmol; 2008 Aug; 92(8):1035-9. PubMed ID: 18653595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.
    Fine HF; Zhitomirsky I; Freund KB; Barile GR; Shirkey BL; Samson CM; Yannuzzi LA
    Retina; 2009 Jan; 29(1):8-12. PubMed ID: 18784620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for choroidal neovascularization associated with choroidal nevus.
    Chiang A; Bianciotto C; Maguire JI; Park CH; Baker PS; Shields JA; Shields CL
    Retina; 2012 Jan; 32(1):60-7. PubMed ID: 21886019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
    Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
    Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up.
    El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N
    Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
    Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
    Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab for uveitic choroidal neovascularization.
    Doctor PP; Bhat P; Sayed R; Foster CS
    Ocul Immunol Inflamm; 2009; 17(2):118-26. PubMed ID: 19412874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of choroidal neovascularization secondary to sorsby fundus dystrophy with intravitreal bevacizumab.
    Gemenetzi MK; Luff AJ; Lotery AJ
    Retin Cases Brief Rep; 2011; 5(2):132-5. PubMed ID: 25389882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.